Business Context and Reporting Period
This Form 8-K was filed by Rexahn Pharmaceuticals, Inc. on March 6, 2019, reporting events occurring on March 4, 2019. The registrant is a Delaware corporation headquartered in Rockville, MD. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
Item 5.02 reports the departure of a senior officer:
- Resignation: Ely Benaim, M.D., resigned as Chief Medical Officer.
- Effective Date: March 31, 2019.
- Reason: To accept the position of Chief Medical Officer at a commercial stage, global oncology company.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the executive departure.
Investor Verification Checklist
- Verify the appointment of a new Chief Medical Officer to replace Dr. Benaim.
- Confirm the impact of this departure on ongoing clinical trials or drug development pipelines.
- Review subsequent filings for any changes in executive compensation or board composition.